Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer Inc

6 Nov 2015 15:22

RNS Number : 9146E
Bank of New York Mellon Corp. (The)
06 November 2015
Β 

Ap19

Β 

Β 

FORMΒ 8.3

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE

Β 

1. KEYΒ INFORMATION

Β 

Name of person dealing (Note 1)

The Bank of New York Mellon Corporation and its subsidiaries, 1.

The Bank of New York Mellon, 2. The Dreyfus Corporation, 3. Mellon Capital Management Corporation, 4. The Boston Company Asset Management LLC, 5. Newton Investment Management Limited, 6. BNY Mellon Capital Markets, LLC, 7. BNY Mellon Service Kapitalanlage-Gesellschaft mbH, 8. The Bank of New York Mellon Trust Company, National Association, 9. BNY Mellon Trust Company (Cayman) Limited, 10. BNY Mellon Trust of Delaware, 11. BNY Mellon, National Association, 12. Lockwood Advisors, Inc., 13. Pershing LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.05 common stock

Date of dealing

05 November 2015

Β 

Β Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

99,723,182 1.6156%

4,124 0.00007%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

12,600 0.0002%

2,200 0.00004%

Total

99,735,782 1.6158%

6,324 0.0001%

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Ap20

Β 

Β 

1. DEALINGSΒ (NoteΒ 4)

Β 

(a) PurchasesΒ andΒ sales

Β 

Β 

Purchase/sale

Β 

Number of relevant securities

Β 

Price per unit (Note 5)

Sale

Sale

Purchase

Purchase

Sale

Transfer Out

Purchase

Purchase

Transfer Out

Sale

Sale

Sale

Purchase

Sale

Transfer Out

5,883

3

3

73,829

68,138

5,000

2,234

1,102

1,481

116,849

75

6,226

134

177

229

USD 34.23

USD 34.25

USD 34.15

USD 34.20

USD 34.20

N/A

USD 34.15

USD 34.15

N/A

USD 34.15

USD 34.15

USD 34.15

USD 34.19

USD 34.18

N/A

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)

Β 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

Β 

2. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

Β 

Β 

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyrelevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisshouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β YES

Β 

Date of disclosure

06 November 2015

Contact name

Andrew Weiser

Telephone number

516-338-3752

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Β 

Β Β 

Β 

Ap23

SUPPLEMENTALΒ FORMΒ 8

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.1Β ANDΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANELΒ ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 8.1(a)Β &Β (b)(i),Β FormΒ 8.1(b)(ii)Β orΒ FormΒ 8.3,Β asΒ appropriate)

Β 

OPENΒ POSITIONSΒ (NoteΒ 1)

Product name,

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

e.g. call option

Call Option

Written

100

USD 28

American

15-Jan-16

Call Option

Purchased

100

USD 31

American

15-Jan-16

Call Option

Written

200

USD 32

American

15-Jan-16

Call Option

Purchased

1,700

USD 36

American

15-Jan-16

Call Option

Purchased

1,000

USD 38

American

15-Jan-16

Call Option

Purchased

600

USD 39

American

15-Jan-16

Put Option

Written

100

USD 28

American

15-Jan-16

Put Option

Written

4,300

USD 32

American

15-Jan-16

Call Option

Written

200

USD 32

American

20-Jan-17

Call Option

Written

100

USD 35

American

20-Jan-17

Call Option

Written

100

USD 40

American

20-Jan-17

Call Option

Written

1,400

USD 34

American

18-Mar-16

Call Option

Purchased

600

USD 35

American

18-Mar-16

Call Option

Purchased

100

USD 36

American

18-Mar-16

Put Option

Written

200

USD 32

American

20-Nov-15

Call Option

Purchased

3,800

USD 32

American

18-Dec-15

Call Option

Written

100

USD 33

American

18-Dec-15

Call Option

Purchased

100

USD 37

American

18-Dec-15

Β 

Notes

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionsΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.FullΒ detailsΒ ofΒ anyΒ existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ must alsoΒ beΒ givenΒ onΒ thisΒ form.

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ must beΒ stated.

Β 

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RuleΒ 8Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEBFBATMBBMBLA
Date   Source Headline
1st Mar 20178:51 amRNSPress Release
27th Feb 201710:45 amRNSPress Release
24th Feb 20172:19 pmRNSPress Release
22nd Feb 20177:00 amRNSCancellation of UK Listing
31st Jan 20172:56 pmRNSFourth Quarter and Full-Year 2016 Results
24th Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
24th Nov 20153:19 pmRNSForm 8.3 - Pfizer, Inc.
24th Nov 201512:14 pmRNSForm 38.5(b) - Pfizer Inc
24th Nov 201511:49 amRNSForm 8.1a - Pfizer Inc
24th Nov 201511:46 amRNSForm 38.5(a) - Pfizer Inc
24th Nov 201510:41 amRNSRule 38.5 - Pfizer INC
24th Nov 20157:00 amRNSForm 38.5(b) - Pfizer Inc
23rd Nov 20156:11 pmRNSForm 38.5(a) - Pfizer Inc
23rd Nov 20155:58 pmRNSForm 8.1a - Pfizer Inc
23rd Nov 20153:40 pmRNSForm 8.3 - PFIZER INC
23rd Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc Amendment
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:28 pmRNSForm 8.3 - ALLERGAN PLC
23rd Nov 20153:21 pmRNSForm 8.3 - Pfizer, Inc.
23rd Nov 20152:56 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:39 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:29 pmRNSForm 8.3 - Allergan Plc
23rd Nov 201512:16 pmRNSForm 8.1 - [Pfizer Inc.]
23rd Nov 201512:04 pmRNSForm 38.5a
23rd Nov 201511:57 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
20th Nov 20153:43 pmRNSForm 8.3 - Pfizer Inc.
20th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
20th Nov 20153:21 pmRNSForm 8.3 - PFIZER INC
20th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
20th Nov 20153:14 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:11 pmRNSForm 8.3 - [PFIZER INC]
20th Nov 20153:07 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20152:58 pmRNSForm 8.3 - Allergan plc
20th Nov 20152:57 pmRNSRule 38.5 - Replacement Pfizer INC
20th Nov 20152:52 pmRNSForm 8.3 - Allergan Plc
20th Nov 20152:44 pmRNSForm 8.3 - Pfizer, Inc.
20th Nov 201512:14 pmRNSForm 8.1 - [Pfizer Inc]
20th Nov 201511:57 amRNSForm 38.5b
20th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
20th Nov 201511:53 amRNSForm 38.5b
20th Nov 201511:53 amRNSForm 38.5(b) - Pfizer Inc
20th Nov 201511:52 amRNSForm 38.5a
20th Nov 201511:18 amRNSForm 38.5(a) - Pfizer Inc
20th Nov 201510:37 amRNSRule 38.5 - Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.